Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4479-4481

  Pachón Ibánẽz, María Eugenia ^a   Jiménez Mejías, Manuel Enrique ^a   Pichardo, Cristina ^a   Llanos, Ana Cristina ^a   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; IN VITRO STUDY; MIC 50; MIC 90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIPENEM; KINETICS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 7244238100     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4479-4481.2004     Document Type: Article

References (20)

1. Bergogne-Bérézin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.
2. Betriu, C., I. Rodríguez-Avial, B. A. Sánchez, M. Gómez, J. Álvarez, J. J. Picazo, and the Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895.
3. Bou, G., G. Cerveró, M. A. Domínguez, C. Quereda, and J. Martínez-Beltran. 2000. Characterization of nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. 38:3299-3305.
4. Cisneros, J. M., M. J. Reyes, J. Pachón, B. Becerril, F. J. Caballero, J. L. García-Garmendia, C. Ortiz, and A. R. Cobacho. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22:1026-1032.
5. Corbellá, X., M. Pujor, J. Ayats, M. Sendra, C. Ardanuy, M. A. Domínguez, J. Liñares, J. Ariza, and F. Gudiol. 1996. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin. Infect. Dis. 23:329-334.
6. Fagon, J. Y., J. Chastre, A. J. Hance, et al. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:281-288.
7. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
8. Garnacho-Montero, J., C. Ortiz-Leyba, F. J. Jiménez- Jiménez, A. E. Barrero-Almodóvar, J. L. García-Garmendia, M. Bernabeu-Wittel, S. L. Gallego-Lara, and J. Madrazo-Osuna. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118.
9. Henwood, C. J., T. Gatward, M. Warner, D. James, M. W. Stockdale, R. P. Spence, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49:479-487.
10. Hoellman, D. B., G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44:1085-1088.
11. Horrevorts, A., K. Bergman, L. Kollee, I. Breaker, I. Tjernberg, and L. Dijkshoorn. 1995. Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. J. Clin. Microbiol. 33:1567-1572.
12. Jacobus, N. V., L. A. McDermott, R. Ruthazer, and D. R. Snydman. 2004. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48:1034-1036.
13. Lortholary, O., J. Y. Fagon, A. B. Hoi, M. A. Slama, J. Pierre, P. Giral, R. Rosenzweig, L. Gutmann, M. Safar, and J. Acar. 1995. Nosocomial acquisition of Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20:790-796.
14. Martín-Lozano, D., J. Cisneros, B. Becerril, L. Cuberos, T. Prados, C. Ortíz-Leyba, E. Cañas, and J. Pachón. 2002. Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia. J. Clin. Microbiol. 40:4571-4575.
15. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikkels, and W. J. Weiss, 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Prodan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
18. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
19. Swenson, J. M., J. Hindler, and L. Peterson. 1999. Special phenotypic methods for detecting antibacterial resistance, p. 1563-1577. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. ASM Press, Washington, D.C.
20. Testa, R., P. J. Petersen, N. V. Jacobus, P. E. Sum, V. J. Lee, and F. P. Tally, 1993. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. 37:2270-2277.